MARKET

NLTX

NLTX

Neoleukin Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.58
+0.35
+3.12%
Closed 16:00 05/07 EDT
OPEN
11.33
PREV CLOSE
11.23
HIGH
11.86
LOW
11.10
VOLUME
106.17K
TURNOVER
--
52 WEEK HIGH
18.13
52 WEEK LOW
9.63
MARKET CAP
490.14M
P/E (TTM)
-17.9229
1D
5D
1M
3M
1Y
5Y
Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial
GlobeNewswire · 3d ago
BRIEF-Neoleukin Therapeutics Announces Initiation Of Phase 1 NL-201 Trial
reuters.com · 3d ago
Neoleukin Therapeutics to Participate in BofA Securities 2021 Healthcare Conference
SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D...
GlobeNewswire · 4d ago
Press Release: Neoleukin Therapeutics Announces Appointment of Priti Patel, M.D., M.S., as Chief Medical Officer
Dow Jones · 5d ago
Analysts Offer Insights on Healthcare Companies: Neoleukin Therapeutics (NLTX) and Sol-Gel Technologies (SLGL)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neoleukin Therapeutics (NLTX) and Sol-Gel Technologies
SmarterAnalyst · 04/28 10:25
Ne­oleuk­in's IL-2 Agonist Candidate Cleared To Start Phase 1 Trial In Solid Tumors
Benzinga · 04/26 14:19
Neoleukin Therapeutics (NLTX) Gets a Buy Rating from Mizuho Securities
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Neoleukin Therapeutics (NLTX) today and set a price target of $21.00. The company's
SmarterAnalyst · 04/26 13:15
Neoleukin Therapeutics Announces Clearance To Proceed With NL-201 Phase 1 Clinical Trial In United States
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that the U.S.
Benzinga · 04/26 11:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NLTX. Analyze the recent business situations of Neoleukin Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NLTX stock price target is 20.40 with a high estimate of 22.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 112
Institutional Holdings: 27.90M
% Owned: 65.92%
Shares Outstanding: 42.33M
TypeInstitutionsShares
Increased
29
2.18M
New
18
403.19K
Decreased
22
1.54M
Sold Out
16
873.71K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Non-Executive Chairman/Independent Director
Todd Simpson
President/Chief Executive Officer/Director
Jonathan Drachman
Chief Financial Officer
Robert Ho
Senior Vice President
Carl Walkey
General Counsel/Secretary
Holly Vance
Other
Priti Patel
Independent Director
Martin Babler
Independent Director
M. Cantey Boyd
Independent Director
Erin Lavelle
Independent Director
Sarah Noonberg
Independent Director
Lewis Williams
No Data
About NLTX
Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.

Webull offers kinds of Neoleukin Therapeutics Inc stock information, including NASDAQ:NLTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NLTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NLTX stock methods without spending real money on the virtual paper trading platform.